Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kenvue Inc. Common Stock (KVUE) vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) Price & Performance

Kenvue Inc. Common StockTrade
RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)Trade

Price performance (Past 24H)

Key statistics

Kenvue Inc. Common Stock vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) — how do they compare? Kenvue Inc. Common Stock trades at $18.08 (market cap $34.11B), while RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $36.73 (market cap $63.57B). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is the larger of the two by market cap, and Kenvue Inc. Common Stock pays the higher dividend (4.73%). Which is the better fit depends on your goals.

KVUERELX
Market Cap
$34.11B$63.57B
Volume
27,388,8111,602,093
Sector
Consumer StaplesIndustrials
52-Week High
$19.83$46.80
52-Week Low
$14.11$27.73
Typical Hold Time
1 Days—
Enterprise Value
$41.62B$75.05B
Dividend Yield
4.73%2.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kenvue Inc. Common Stock

Kenvue (KVUE) trades at $17.76, down 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $15.12B in 2025, with a net income margin of 10.76% and a P/E ratio of 20.89. Recent news highlights conditional EU approval for Kimberly-Clark's $40B acquisition of Kenvue, potentially impacting future operations and shareholder returns.

The outlook is mixed, with strong profitability and consistent dividend payments offering stability, but the pending acquisition introduces uncertainty. Risks include integration challenges and market volatility. Analyst consensus is a Hold with a $19.50 price target, suggesting limited near-term upside from current levels.

RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)

RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.

The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kenvue Inc. Common Stock

Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.

Read more on KVUE →

About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)

RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.

Read more on RELX →